MetaVia Inc (MTVA)

• Market cap: $7.44M
• 1 day: 1.41%
• 5 days: -3.36%
• 1 month: 18.03%
• 3 months: -20.88%
• 6 months: -84.6%
• Year to date: -84.94%
• 1 year: -82.33%
• 5 years: -99.98%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.

Employees: 8